Dr. Huifang Dai is a distinguished pharmaceutical researcher, bringing a wealth of academic accomplishments and international recognition to the field. With a robust academic background, Dr. Dai earned her PhD from Fudan University and conducted postdoctoral research at Stanford University, marking the beginning of a journey marked by excellence and innovation.

Throughout her illustrious career, Dr. Dai held positions at prestigious institutions such as UC-Berkeley and UW-Madison, solidifying her status as a seasoned professional in the pharmaceutical research arena. Currently affiliated with Fudan University's School of Pharmacy, she serves as a beacon of knowledge and expertise in the realm of drug development.

Dr. Dai's specialization lies in the asymmetric synthesis of natural and biologically active compounds, with a particular focus on anti-cancer agents. Her groundbreaking research in this field has not only contributed to the advancement of scientific knowledge but has also earned her prestigious awards, including recognition from the Chinese National Science & Technology Achievement and the Ministry of Education.

In her capacity as the Senior Vice President (SVP) for China at the American Botanical Drug Association (ABDA), Dr. Dai showcases her leadership and expertise in bridging the gap between Chinese herbal medicine and international botanical drug development. Her role involves facilitating collaboration, fostering partnerships, and contributing to the global dialogue on pharmaceutical advancements.

Dr. Mary Dai's commitment to advancing pharmaceutical research and fostering international collaboration underscores her dedication to pushing the boundaries of scientific discovery. Her role at the intersection of academia and industry positions her as a catalyst for innovation and a key player in the dynamic landscape of botanical drug development. Through her leadership at ABDA, Dr. Brown continues to shape the narrative of global pharmaceutical collaboration, leaving an indelible mark on the future of healthcare advancements.